

- in neurologic disorders, 191
 psychiatric disorders and, 190
 psychophysiological factors in, 190
 sleep hygiene and, 190
 in terminally ill patient, 65
 treatment of, 65, 191–192, 191t
- Institute of Medicine (IOM), 16e-2, 16e-5–6
- Instrumental activities of daily living (IADLs), 72t, 78t
- Insulin. *See also* Insulin therapy
 action of, 2402–2403, 2430, 2431t
 biosynthesis of, 2402
 ectopic production of, 609t
 effectors of, 400e-1t
 reference values for, 2761t
 secretion of, 2402, 2402f, 2405
 in sepsis/septic shock, 1758
 signaling pathways of, 400e-1t
 structure of, 400e-1
- Insulin aspart, 2411, 2411t
- Insulin autoimmune syndrome (Hirata's syndrome), 2348
- Insulin-dependent diabetes mellitus (IDDM). *See* Diabetes mellitus, type 1
- Insulin detemir, 2411, 2411t
- Insulin glargine, 2411, 2411t
- Insulin glulisine, 2411, 2411t
- Insulin-like growth factor (IGF), in aging, 85, 94e-5
- Insulin-like growth factor I (IGF-I)
 action of, 401e-3, 401e-4
 adverse effects of, 401e-4
 factors affecting levels of, 401e-3
 in gastroduodenal mucosal defense and repair, 1913f
 injected, 401e-4
 pNET secreting, 559t, 571
 signal transduction pathway for, 400e-1t
 structure of, 400e-1
 in thyroid hormone synthesis, 2285
- Insulin-like growth factor II (IGF-II)
 action of, 401e-3
 ectopic production of, 609t, 611–612
 in sarcoma, 119e-1
- Insulin-like growth factor II gene, 439, 611
- Insulin lispro, 2411, 2411t
- Insulinoma, **569**
 clinical features of, 559t, 569, 2337
 diagnosis of, 569, 2337, 2434
 endogenous hyperinsulinism due to, 2434
 incidence of, 559t, 2434
 in MEN 1, 2337–2338
 obesity in, 415e-4
 screening tests for, 2337t
 treatment of, 569, 2338, 2434
- Insulinomatosis, 569
- Insulin receptor, 372e-24t
- Insulin receptor substrates, 2403
- Insulin resistance
 atherosclerosis and, 291e-6
 autoimmune, 372e-24t, 377e-4, 2348
 colorectal cancer and, 538
 fecal microbiota transplantation for, 86e-10
 free fatty acids in, 2450
 lipoprotein disorders and, 2438, 2439
 in metabolic syndrome. *See* Metabolic syndrome
 obesity and, 415e-6
 in pregnancy, 48
 specialized nutritional support and, 98e-4
 syndromes of, 2405–2406
 treatment of, 2454
- Insulin secretagogues
 incretins, 2414–2415, 2414t, 2416
 sulfonylureas. *See* Sulfonylureas
 for type 2 diabetes mellitus, 2414t
- Insulin therapy
 adverse effects of, 2392
 for diabetic ketoacidosis, 64e-1
 for DKA, 2419
 for hyperkalemia, 312
 hypokalemia and, 305
 with parenteral nutrition, 98e-7
 in pregnancy, 48
 for type 1 diabetes mellitus, 2411–2412, 2411t, 2412f
 for type 2 diabetes mellitus, 2414t, 2415–2416
- Insulin tolerance test, 2310–2311
- Integrase, 1217
- Integrase inhibitors. *See* Combination antiretroviral therapy (cART)
- Integrative medicine, 14e-1–2. *See also* Complementary and alternative medicine
- Integrin(s)
 of innate immune system, 372e-2
 in neutrophil adhesion, 416
 stem cell, 89e-1, 139e-1
 in tumor angiogenesis, 102e-14f, 102e-15, 102e-16f, 102e-17t
- Integrin $\alpha 4\beta 7$, 1234–1235
- Intensity-modulated radiation therapy, 583
- Intensivists, 5, 1729
- Interactome, 87e-7f
- Intercalated cells, 332e-5f, 332e-9
- Intercellular adhesion molecule 1 (ICAM-1), 1242, 2170
- Interdigitating dendritic cell sarcoma (reticulum cell sarcoma), 135e-9
- Interferon(s)
 genetic variations in response to, 39t
 pharmacology of, 215e-10
 structure of, 372e-16
 in viral infections, 214e-8, 215e-10
- Interferon- α (IFN- α)
 action and targets of, 103e-22
 for adult T-cell leukemia/lymphoma, 225e-5
 adverse effects of, 103e-22, 567, 574, 2033
 cardiac, 1563
 cutaneous, 378, 379, 381
 depression, 63
 for carcinoid syndrome, 567
 for chronic HBV infection, 2033
 for chronic HCV infection, 2041–2043, 2042f
 for chronic HDV infection, 215e-10, 2040
 for CML, 694
 for follicular lymphoma, 705
 for genital warts, 1201, 1201t
 for hypereosinophilic syndromes, 423
 for Kaposi's sarcoma, 1270, 1270t
 for NETs, 574
 for polycythemia vera, 674
 production of, 372e-6
 for renal cell carcinoma, 579
 source, target, and biologic activity of, 372e-11t
 for systemic mastocytosis, 2121
 thyroid dysfunction, 2299
 for viral hemorrhagic fever, 261e-8
- Interferon- $\alpha 2a$ (IFN- $\alpha 2a$)
 adverse effects of, 498
 for chronic HCV infection, 215e-4t, 215e-10
 for chronic HDV infection, 215e-5t
 for melanoma, 498
 pegylated. *See* Pegylated interferon- $\alpha 2a$ (PEG IFN- $\alpha 2a$)
- Interferon- $\alpha 2b$ (IFN- $\alpha 2b$)
 for chronic HBV infection, 215e-4t, 215e-10
 for chronic HCV infection, 215e-4t
 for chronic HDV infection, 215e-5t
 for condyloma acuminatum, 215e-4t
 pegylated. *See* Pegylated interferon- $\alpha 2b$ (PEG IFN- $\alpha 2b$)
- Interferon- $\alpha n3$ (IFN- $\alpha n3$), for condyloma acuminatum, 215e-4t
- Interferon- β (IFN- β)
 adverse effects of, 2667
 for MS, 2667, 2669t, 2671
 in pregnancy, 49
 source, target, and biologic activity of, 372e-11t
- Interferon- $\beta 1a$ (IFN- $\beta 1a$), 2667–2668, 2669t
- Interferon- $\beta 1b$ (IFN- $\beta 1b$), 2667–2668, 2669t
- Interferon- γ (IFN- γ)
 in *Brucella* infections, 194e-2
 for chronic granulomatous disease, 372e-30, 423
 in HIV infection, 422
 indications for, 423
 in nontuberculous mycobacterial infections, 1129, 1129f
 for Q fever, 1162
 source, target, and biologic activity of, 372e-11t
 suppression of erythropoietin production by, 630, 630f
 in T-cell lymphoma, 422
- Interferon- γ (IFN- γ) release assays (IGRAs), 138, 1115, 1131
- Interferon spray, 1203
- Interleukin(s), 372e-10–11t, 372e-14, 372e-14t, 413
- Interleukin-1 (IL-1)
 in anemia of inflammation, 630
 in familial Mediterranean fever, 422
 in fever induction, 124, 125f, 141
 in pneumonia, 804
 source, target, and biologic activity of, 372e-10t
- Interleukin-1 receptor antagonist (IL-1Ra)
 deficiency of, 2215
 recombinant. *See* Anakinra
- Interleukin-1 receptor-associated kinase (IRAK-4), 145e-5, 145e-6f, 950
- Interleukin-1 β (IL-1 β)
 in HIV infection, 1235
 in osteoarthritis, 2227, 2227f
 in sepsis/septic shock, 1752
- Interleukin-2 (IL-2), 372e-10t
- Interleukin-2 (IL-2) therapy
 action and targets of, 103e-22
 adverse effects of, 63, 103e-22, 253t, 379, 621, 2299
 for melanoma, 103e-22, 498
 for renal cell carcinoma, 103e-22, 579
- Interleukin-3 (IL-3), 372e-10t
- Interleukin-4 (IL-4), 372e-10t
- Interleukin-5 (IL-5), 372e-10t, 422, 1673
- Interleukin-6 (IL-6)
 age-related changes in levels of, 75, 75f
 in depression, 465e-4
 excess of, 612
 in fever induction, 124, 125f
 in HIV infection, 1240t, 1249t
 in sepsis/septic shock, 1753
 source, target, and biologic activity of, 372e-10t
- Interleukin-7 (IL-7), 372e-10t, 1237
- Interleukin-8 (IL-8), 372e-10t, 416–417, 1701
- Interleukin-9 (IL-9), 372e-10t
- Interleukin-10 (IL-10), 372e-10t, 1240t, 1753
- Interleukin-11 (IL-11), 103e-23, 372e-10t
- Interleukin-12 (IL-12), 372e-10t, 1129, 1129f
- Interleukin-13 (IL-13), 372e-10t
- Interleukin-14 (IL-14), 372e-10t
- Interleukin-15 (IL-15), 39t, 372e-10t
- Interleukin-16 (IL-16), 372e-10t
- Interleukin-17 (IL-17), 372e-10t, 2141, 2142f
- Interleukin-18 (IL-18), 372e-10t, 1752, 1808
- Interleukin-21 (IL-21), 372e-10t
- Interleukin-22 (IL-22), 372e-10t
- Interleukin-23 (IL-23), 372e-10t
- Interleukin-24 (IL-24), 372e-11t
- Interleukin-25 (IL-25; IL-17E), 372e-11t
- Interleukin-26 (IL-26), 372e-11t
- Interleukin-28B (IL-28B), 39t
- Interleukin-36 (IL-36) receptor antagonist, 2215
- Intermediate-density lipoproteins (IDLs), 1241t, 2436–2437, 2436f, 2436t
- Intermediate metabolizers, 40
- Intermittent mandatory ventilation (IMV), 1741–1742, 1742t. *See also* Mechanical ventilation
- Internal carotid artery, 2574, 2574f, 2575f
- International Cancer Genome Consortium, 101e-8
- International Classification of Functioning, Disability, and Health, 78–79